Motif's CEO on business leap from discovery to clinical-stage biotech

Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeutics for infectious diseases, talks with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about the company's history, a development timeline for its leading drug candidate, Iclaprim, and why Motif recently decided to jump from being a drug discovery company to a clinical-stage biotech. Motif's lead product, which has just entered Phase III trials, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae).

Interviewer: Mike Ward – Global Director of Content, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Graham Lumsden – CEO, Motif Bio